Schlieren / Zurich, Switzerland, 9 February, 2026 – Memo Therapeutics AG  ("MTx") today announced it has entered into a strategic collaboration and exclusive option-to-license agreement with CSL, a global leader in developing and delivering high-quality medicines that treat people with rare and serious diseases, for MTx's recombinant polyclonal IgG technology.

NEW YORK, January, 28th, 2026 – Sword Health, the world's leading AI Health company, today announced the acquisition of Kaia Health, a digital health company focused on musculoskeletal (MSK) and pulmonary care, in a deal valued at $285 million. The acquisition reinforces Sword's position as the fastest-growing AI Care platform in the world, expanding its ability to deliver high-quality, scalable care to new populations in the US while entering the German market.

Schlieren / Zurich, Switzerland, 9 January, 2026 – Memo Therapeutics AG ("MTx"), a late-stage biotech company translating unique human immune responses into superior medicines to treat viral infections and cancer, today announces the publication of a qualitative research paper titled 'Development of a Conceptual Model of BKV Impacts on Health-Related Quality of Life in Kidney Transplant Recipients' in the Journal of Patient-Reported Outcomes.

Schlieren / Zurich, Switzerland, 18 December, 2025 – Memo Therapeutics AG ("MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces that the European Commission has granted orphan designation in the European Union (EU) for potravitug, a highly potent human BK polyomavirus ("BKPyV")-neutralizing antibody for the treatment of BKPyV infection in kidney transplant recipients.

Schlieren / Zurich, Switzerland, 7 November, 2025 – Memo Therapeutics AG ("MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces that it has presented long term follow-up data from its Phase II SAFE KIDNEY trial of therapeutic antibody potravitug for the treatment of BK polyomavirus (BKPyV) infection in kidney transplant recipients (KTRs) at the American Society of Nephrology (ASN) Kidney Week Meeting from November 5–9, 2025, in Houston, Texas.

November 07, 2025 – Published at 9.00 am ET / 3.00 pm CET – We are excited to share that our Phase 1/2 GDFATHER-01 trial evaluating our lead candidate Visugromab in various solid tumor indications will be highlighted across multiple presentations at the upcoming SITC Annual Meeting 2025.

Munich, Germany and San Francisco, USA, October 20, 2025 – CatalYm today announced updated long-term data from its ongoing GDFATHER-1/2a trial (NCT04725474) at the European Society of Medical Oncology (ESMO) Congress 2025. The data provide further evidence that Growth Differentiation Factor-15 (GDF-15) blockade by visugromab can reverse resistance to PD-(L)1 treatment in patients with advanced solid tumors and deliver durable responses in patients who have relapsed or progressed on prior checkpoint inhibitor treatment.

Munich, Germany and San Francisco, USA, October 17, 2025 – CatalYm today presented compelling primary results from the Phase 2 GDFATHER-NEO trial in an oral late-breaking session at the European Society of Medical Oncology (ESMO) Congress 2025. The data demonstrated that Growth Differentiation Factor-15 (GDF-15) blockade by visugromab enhanced the efficacy of PD-1 inhibition by nivolumab as a neoadjuvant therapy in muscle-invasive bladder cancer (MIBC), with a similar safety profile compared to nivolumab plus placebo.

Munich, Germany and San Francisco, USA, September 30, 2025 – CatalYm today announced that the first patient has been dosed in the randomized Phase 2b GDFATHER-NSCLC-01 trial (NCT07098988). The trial investigates the efficacy and safety of the company's anti-GDF-15 antibody visugromab, in combination with standard-of-care chemoimmunotherapy, compared to placebo plus chemoimmunotherapy, as a first-line treatment for patients with newly diagnosed metastatic non-squamous non-small cell lung cancer (NSQ mNSCLC).

MUNICH & SAN FRANCISCO--(BUSINESS WIRE) September 23, 2025 – CatalYm, a world-leader in neutralizing GDF-15 in cancer and cachexia, today announced two upcoming oral presentations highlighting the company's lead-candidate visugromab at the European Society of Medical Oncology (ESMO) Congress, being held October 17^th - 21^st, 2025, in Berlin, Germany.